Fundraising FoxVerona Pharma
London · United Kingdom corporation · 11 known investors
Find your way into Verona Pharma
116 people in our graph can introduce you to the Verona Pharma team.
Sign up to see every warm intro you have to Verona Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Verona Pharma team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Verona Pharma develops treatments for chronic lung conditions. As of October 2025, it and its subsidiaries are part of Merck & Co., Inc.
Founders & leadership
Board
Investors · 11
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$244.7M disclosed across 2 rounds · 2016–2020
▶$200.2MraisedJul 2020 · 43 investors · PharmaceuticalsRule 506(b)
- Andrew SinclairDirector
- Mahendra ShahDirector
- Rishi GuptaDirector
- David EbsworthDirector
- Mark W. HahnExecutive Officer
- Kathleen RickardExecutive Officer
- Anders UllmanDirector
- Claire PollExecutive Officer
- Martin EdwardsDirector
- Ken CunninghamDirector
- David ZaccardelliExecutive Officer, Director
- Vikas SinhaDirector
- Offering amount
- $200.2M
- Amount sold
- $200.2M
- Sales commissions
- $12M
- Placement agents
- JEFFERIES LLC, CANACCORD GENUITY LLC, WEDBUSH SECURITIES INC., BTIG, LLC
- First sale
- Jul 2020
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$44.5MraisedJul 2016 · 8 investors · PharmaceuticalsRule 506(b)
- Jan-Anders KarlssonExecutive Officer, Director
- David EbsworthDirector
- Patrick HumphreyDirector
- Peter SpargoExecutive Officer
- Ken CunninghamDirector
- Kenneth NewmanExecutive Officer
- Anders UllmanDirector
- Offering amount
- $44.5M
- Amount sold
- $44.5M
- Minimum investment
- $421K
- Sales commissions
- $2.9M
- Placement agents
- MTS SECURITIES, LLC
- First sale
- Jun 2016
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Verona Pharma do?
- Verona Pharma develops treatments for chronic lung conditions. As of October 2025, it and its subsidiaries are part of Merck & Co., Inc.
- Who are Verona Pharma's investors?
- Verona Pharma's investors include Access Biotechnology, Aisling Capital, Andera Partners, Foresite Capital, Frazier Life Sciences, New Enterprise Associates (NEA), Sofinnova Partners, venBio Partners and 3 more.
- How much funding has Verona Pharma raised?
- Verona Pharma has disclosed $244.7M raised across 2 rounds.
- Where is Verona Pharma headquartered?
- Verona Pharma is headquartered in London.